User:Mr. Ibrahem/Lasmiditan
 | |
| Clinical data | |
|---|---|
| Trade names | Reyvow |
| Other names | COL-144 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a620015 |
| License data |
|
| Routes of administration | By mouth |
| Drug class | 5-HT1F receptor activator[1] |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C19H18F3N3O2 |
| Molar mass | 377.367 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Lasmiditan, sold under the brand name Reyvow, is a medication used to treat migraine headaches.[3] It is not useful for prevention.[3] It is taken by mouth.[3] It is less effective and more expensive than sumatriptan.[4]
Common side effects include dizziness, tiredness, and numbness.[1] Other side effects may include serotonin syndrome, medication overuse headaches, and poor coordination.[1] It has a low risk for misuse.[3] Safety in pregnancy is unclear.[3] It is a 5-HT1F receptor activator.[1]
Lasmiditan was approved for medical use in the United States in 2019.[3] In the United States it costs about 83 USD per 100 mg dose as of 2021.[5] It is not available in the United Kingdom or Europe as of 2021.[4]
References[edit]
- ^ a b c d e "Reyvow- lasmiditan tablet". DailyMed. 11 October 2019. Archived from the original on 25 November 2020. Retrieved 15 November 2019.
- ^ "2020 - Placement of Lasmiditan in Schedule V". DEA Diversion Control Division. 31 January 2020. Archived from the original on 31 January 2020. Retrieved 31 January 2020.
- ^ a b c d e f g h "Lasmiditan Monograph for Professionals". Drugs.com. Archived from the original on 23 January 2021. Retrieved 21 November 2021.
- ^ a b "Lasmiditan". SPS - Specialist Pharmacy Service. 30 December 2015. Archived from the original on 21 November 2021. Retrieved 21 November 2021.
- ^ "Reyvow Prices and Reyvow Coupons - GoodRx". GoodRx. Retrieved 21 November 2021.